These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11504270)

  • 1. Oral bioavailability and disposition of [14C]omapatrilat in healthy subjects.
    Malhotra BK; Iyer RA; Soucek KM; Behr D; Liao WC; Mitroka JG; Kaul S; Cohen MB; Knupp CA
    J Clin Pharmacol; 2001 Aug; 41(8):833-41. PubMed ID: 11504270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and pharmacokinetics of omapatrilat in heart failure.
    Kostis JB; Klapholz M; Delaney C; Vesterqvist O; Cohen M; Manning JA; Jemal M; Kollia GD; Liao WC
    J Clin Pharmacol; 2001 Dec; 41(12):1280-90. PubMed ID: 11762555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition and safety of omapatrilat in subjects with renal impairment.
    Sica DA; Liao W; Gehr TW; Khan S; Jemal M; Delaney CL; Ferreira IM; Malhotra BK
    Clin Pharmacol Ther; 2000 Sep; 68(3):261-9. PubMed ID: 11014407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.
    Liao WC; Vesterqvist O; Delaney C; Jemal M; Ferreira I; Ford N; Swanson B; Uderman H
    Br J Clin Pharmacol; 2003 Oct; 56(4):395-406. PubMed ID: 12968984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of [(14)C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans.
    Iyer RA; Mitroka J; Malhotra B; Bonacorsi S; Waller SC; Rinehart JK; Roongta VA; Kripalani K
    Drug Metab Dispos; 2001 Jan; 29(1):60-9. PubMed ID: 11124231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass balance study of [14C]M100240, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy male subjects.
    Shah B; Emmons G; Rohatagi S; Martin NE; Jensen BK
    Am J Ther; 2003; 10(5):356-62. PubMed ID: 12975720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, absorption, metabolism, and excretion of [
    Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H
    Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [
    Guerini E; Schadt S; Greig G; Haas R; Husser C; Zell M; Funk C; Hartung T; Gloge A; Mallalieu NL
    Xenobiotica; 2017 Feb; 47(2):144-153. PubMed ID: 27123695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of zofenopril calcium in healthy subjects.
    Singhvi SM; Foley JE; Willard DA; Morrison RA
    J Pharm Sci; 1990 Nov; 79(11):970-3. PubMed ID: 2292772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
    Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects.
    Nave R; Bethke TD; van Marle SP; Zech K
    Clin Pharmacokinet; 2004; 43(7):479-86. PubMed ID: 15139796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative biotransformation of radiolabeled [(14)C]omapatrilat and stable-labeled [(13)C(2)]omapatrilat after oral administration to rats, dogs, and humans.
    Iyer RA; Malhotra B; Khan S; Mitroka J; Bonacorsi S; Waller SC; Rinehart JK; Kripalani K
    Drug Metab Dispos; 2003 Jan; 31(1):67-75. PubMed ID: 12485955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
    Abel S; Russell D; Whitlock LA; Ridgway CE; Nedderman AN; Walker DK
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):60-7. PubMed ID: 18333867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
    Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
    Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omapatrilat in patients with hepatic cirrhosis. Pharmacodynamics and pharmacokinetics.
    O'Grady P; Vesterqvist O; Malhotra B; Manning J; Jemal M; Ge G; Mangold B
    Eur J Clin Pharmacol; 2001 Jun; 57(3):249-57. PubMed ID: 11497341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.
    Rohatagi S; Shah B; Zhang J; Zeng Z; Kirkesseli S; Jensen BK
    J Clin Pharmacol; 2004 Apr; 44(4):348-58. PubMed ID: 15051741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of age and gender on the pharmacodynamics of omapatrilat in healthy volunteers.
    Liao W; Vesterqvist O; Manning J; Hammett JL; Ferreira IM; Meier A; Davis KD; Hutman HW
    Am J Geriatr Cardiol; 2001; 10(1):50-4. PubMed ID: 11413936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and ADME Characterization of Intravenous and Oral [
    Zamek-Gliszczynski MJ; Kenworthy D; Bershas DA; Sanghvi M; Pereira AI; Mudunuru J; Crossman L; Pirhalla JL; Thorpe KM; Dennison JMTJ; McLaughlin MM; Allinder M; Swift B; O'Connor-Semmes RL; Young GC
    Drug Metab Dispos; 2021 Dec; 49(12):1109-1117. PubMed ID: 34625435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of radiolabeled BMS-204352 in rats and dogs.
    Krishna R; Yao M; Srinivas NR; Shah V; Pursley JM; Arnold M; Vachharajani NN
    Biopharm Drug Dispos; 2002 Jan; 23(1):41-6. PubMed ID: 11891672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
    Seaber E; On N; Dixon RM; Gibbens M; Leavens WJ; Liptrot J; Chittick G; Posner J; Rolan PE; Pack RW
    Br J Clin Pharmacol; 1997 Jun; 43(6):579-87. PubMed ID: 9205817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.